YB4P Stock Chart & Stats
€4.71
-€0.11(-2.27%)
At close: 4:00 PM EDT
€4.71
-€0.11(-2.27%)
Day’s Range― - ―
52-Week Range€2.86 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€887.41M
Enterprise Value€1.42B
Total Cash (Recent Filing)€173.03M
Total Debt (Recent Filing)€30.11M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding205,460,020
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.98Price Target Upside111.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.54
Revenue Forecast (FY)€2.40M
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage reduces the immediate burden of debt service and leaves the company less exposed to balance-sheet stress than many development-stage businesses. This provides some financial flexibility while Savara advances its pipeline and seeks additional funding.
Positive Equity CushionPositive equity provides a capital cushion against the company’s debt obligations and supports continued operation while development programs remain pre-commercial. Although equity has declined, the balance sheet still offers more financial support than a deeply insolvent structure.
Focused Rare-Disease PipelineA concentrated focus on a defined rare respiratory disease and a single lead therapy can help direct research resources toward a clear clinical objective. If development succeeds, specialization may support an identifiable commercial opportunity in an underserved patient population.
Bears Say
No Commercial RevenueWithout an approved product or recurring sales, Savara has no operating revenue to fund research, administration, or future commercialization. The business therefore remains dependent on successful clinical development and continued access to external capital over the next several quarters.
Widening LossesThe widening loss profile shows that operating costs are increasing faster than the company’s ability to generate resources, with no product revenue offset. Sustained losses can lengthen the path to profitability and increase the amount of financing required before commercialization.
High Cash BurnPersistent and escalating negative free cash flow means Savara is consuming substantial capital to maintain operations rather than self-funding growth. Continued burn raises the importance of repeated capital raises and can constrain development choices if financing becomes less available.
Savara News
YB4P FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was €2.86 and its highest was €5.90 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is €887.41M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Aug 11, 2026. The company reported -€0.143 earnings per share for the quarter, missing the consensus estimate of -€0.127 by -€0.016.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.15.
How many shares outstanding does Savara have?
Savara has 205,460,020 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -€0.143 in its last earnings report, missing expectations of -€0.127. Following the earnings report the stock price went down -2.725%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in DE:YB4P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.98 (111.94% Upside)
€9.98 (111.94% Upside)
Blogger Sentiment
Bullish
DE:YB4P Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.17%
12-Months-Change
Fundamentals
Return on Equity
-90.28%
Trailing 12-Months
Asset Growth
17.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
YB4P Stock 12 Month Forecast
Average Price Target
€9.98
▲(111.94% Upside)
Technical Analysis
Omeros
―
Gyre Therapeutics
―
Innoviva
―
4D Molecular Therapeutics
―
Avalyn Pharma Inc
―